Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA's Rulemaking To-Do List Includes Dampening Pedigrees, Boosting Electronic Labeling

You may also be interested in...



Drug Sample Distribution Reporting Deadline Extended By FDA

FDA is giving manufacturers six more months to provide HHS with information on the distribution of drug samples as it plans further guidance; the Affordable Care Act mandated that the data be submitted by April 1.

E-Submission Part Of FDA Reg Reform Plan; Alzheimer’s Data Standard About To Debut

Standards for organizing clinical data from research in some major diseases are taking shape as FDA moves to clear a regulatory path that eventually could allow all submissions to be done electronically.

E-Submission Part Of FDA Reg Reform Plan; Alzheimer’s Data Standard About To Debut

Standards for organizing clinical data from research in some major diseases are taking shape as FDA moves to clear a regulatory path that eventually could allow all submissions to be done electronically.

Related Content

Topics

UsernamePublicRestriction

Register

OM009724

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel